Pierrepont Therapeutics raised $2.41 million in venuture funding to advance PTI-501, its intracellular enzyme replacement therapy for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), a rare mitochondrial disease with no approved treatments.
Investment Amount (In Millions): $2.41